Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Stemline, LLS To Collaborate on BPDCN Treatment | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Stemline, LLS To Collaborate on BPDCN Treatment

Will develop treatment to target cancer stem cells

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Stemline Therapeutics, Inc. (STML) and The Leukemia & Lymphoma Society (LLS) will collaborate to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics. LLS has committed more than $3 million to support this effort, as well as providing a comprehensive educational program to increase physician and patient awareness of BPDCN.

SL-401, a novel targeted therapy directed to cancer stem cells (CSCs) and tumor bulk, has demonstrated efficacy in patients with advanced AML and BPDCN. This includes multiple durable complete responses (CRs) in both indications, a greater than 80% overall response rate (ORR) in BPDCN to date, and an improvement in overall survival (OS) of third-line AML patients relative to historical data.

“The development of SL-401, a novel targeted therapy directed to both tumor bulk and cancer stem cells, would be a significant advancement in the treatment of hematologic cancers that are among those most difficult to treat,” said Lee Greenberger, Ph.D., LLS’s chief scientific officer. “Our partnership with Stemline, funded under the Therapy Acceleration Program at LLS, is an excellent fit with LLS’s initiative to expedite the development of cutting edge therapies for patients with blood cancers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics